| (210) | Number of the EPO application | 18709192 |
| (220) | Filing date of the EPO application | 2018.01.19 |
| (80) | EPO patent specification publication (B) | EPB nr. 12/2025, 2025.03.19 |
| (110) | EPO patent number | 3570840 |
| (21) | Number of the application | e 2019 1314 |
| (71) | Name(s) of applicant(s), code of the country | EXELIXIS, INC., US; |
| (72) | Name(s) of inventor(s), code of the country | SCHWAB Gisela, US;
SCHEFFOLD Christian, US;
HESSEL Colin, US; |
| (73) | Name(s) of owner(s), code of the country | EXELIXIS, INC., US; |
| (54) | Title of the invention | COMBINATIONS OF CABOZANTINIB AND ATEZOLIZUMAB FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 31/47 (2006.01.01); A61K 39/39 (2006.01.01); A61K 9/20 (2006.01.01); A61K 39/00 (2006.01.01); A61K 39/395 (2006.01.01); A61K 45/06 (2006.01.01); A61P 35/00 (2006.01.01); A61P 35/04 (2006.01.01); C07K 16/28 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2020.01.31 |
| (30) | Priority | 201762448869 P, 2017.01.20, US; 201762458447 P, 2017.02.13, US |
| (86) | International application | PCT/US2018/014523, 2018.01.19 |
| (87) | International publication | WO 2018/136796, 2018.07.26 |